Mendus

Regulatoriskt pressmeddelande2026-05-27 15:10

Mendus AB (publ) has resolved to transfer own shares

Mendus

Regulatoriskt pressmeddelande2026-05-27 15:10

Mendus AB (publ) har beslutat om överlåtelse av egna aktier

Mendus

Pressmeddelande2026-05-11 08:28

Redeye: Mendus (Q1 review): CML Phase I Initiated

Mendus

Aktieanalys utförd av tredje part2026-05-11 07:28

Mendus: Clinical expansion initiated; Q126 results - Edison

Mendus’s Q126 results reflect the execution of its expanded clinical strategy for vididencel, with the key highlight being the launch of the Phase I VITAL-CML trial in chronic myeloid leukaemia (CML), marking the start of clinical development in this...

Mendus

Webcast2026-05-08 12:00

Mendus, Audiocast, Q1'26

Mendus

Regulatoriskt pressmeddelande2026-05-08 07:53

Kommuniké från årsstämma i Mendus AB (publ) den 8 maj 2026

Mendus

Regulatoriskt pressmeddelande2026-05-08 06:00

Mendus AB Interim Report January – March 2026

Mendus

Regulatoriskt pressmeddelande2026-05-08 06:00

Mendus AB Delårsrapport januari – mars 2026

Mendus

Regulatoriskt pressmeddelande2026-04-17 06:00

Mendus publishes Annual Report for 2025

Mendus

Regulatoriskt pressmeddelande2026-04-17 06:00

Mendus publicerar årsredovisning för 2025

Mendus

Aktieanalys utförd av tredje part2026-04-09 14:31

Mendus: CML programme commences - Edison

Mendus has announced the launch of its chronic myeloid leukaemia (CML) programme for lead immunotherapy candidate, vididencel. Preparations have been completed and regulatory clearance has been received for the Phase I VITAL-CML study, which will assess...

Mendus